E
Evox Therapeutics
Exosome-based gene editing therapies for neurological diseases
About Evox Therapeutics
Evox Therapeutics is a biotechnology startup that operates in the healthcare sector, specifically focusing on the development of exosome therapeutics. Exosomes are tiny vesicles that cells use to communicate with each other, and Evox is leveraging this natural delivery system to create treatments for serious, life-threatening rare diseases. These are conditions that currently have limited treatment options, making Evox's work potentially life-changing for patients and their families.
Read full description
Evox's business model revolves around its proprietary DeliverEX™ platform, which combines the delivery capabilities of exosomes with targeting technology and advanced biomolecular engineering. This platform is used to develop a pipeline of therapeutics, both internally and in partnership with other companies. By partnering with other firms, Evox can both leverage their expertise and resources, and also provide them with access to its innovative technology.
The company's revenue comes from two main sources. First, from the development and eventual sale of its own therapeutics. Second, from partnerships with other companies who pay to use the DeliverEX™ platform or to co-develop therapeutics.
In summary, Evox Therapeutics is a pioneering biotech firm that's using its unique technology to create treatments for rare diseases. It operates in a niche but important market, and its business model combines internal development with strategic partnerships.
At a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Oxford, United Kingdom
- Employees
- 44
- Open positions
- None listed
- Dealroom signal
- 73.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Research and Development, Spinout, Biotech and Pharma, Rare Diseases, Hard Tech, proteomics, DT and LS, uk is8 life sciences
- Technology
- Nanotech
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Jun 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Feb 2021 | $91M | $365M | Invus · OrbiMed · Cowen Healthcare Investments · Redmile Group | — |
| CONVERTIBLEOther financing | Jun 2020 | $10M | — | Lilly Ventures | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Evox Therapeutics is 5.5K monthly website visits, up 52.8% over the last three months. Evox Therapeutics's team declined 4.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 KinomicaPhosphoproteomic diagnostic platform for precision oncology therapy selection |
Macclesfield, United Kingdom | Operational | 26 | $6.9M | $21M |
 WaveBreakSmall-molecule therapeutics for neurodegenerative diseases |
Cambridge, United Kingdom | Operational | |||
 SpyBiotechNovel vaccine platform using protein superglue technology |
Oxford, United Kingdom | Operational | |||
 Caldan TherapeuticsDevelops innovative therapeutics targeting Type 2 Diabetes |
Edinburgh, United Kingdom | Closed | |||
 IkarovecBi-functional gene therapies for chronic eye diseases |
Norwich, United Kingdom | Operational | |||
 Amphista TherapeuticsNext-generation therapeutics for targeted protein degradation |
Great Abington, United Kingdom | Operational | |||
 MedisieveMagnetic blood filtration enhancing gene therapy efficacy. |
London, United Kingdom | Operational | |||
 SansanimaHuman cell-based assays replacing animal testing. |
Sheffield, United Kingdom | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Oxford Science Enterprises
Redmile Group
Cowen Group- PAPanacea Capital Advisors
- BVBorealis Ventures
Oxford University Innovation
Lilly Ventures
Series B and later4 investors entered at this stage
Invus
OrbiMed- CICowen Healthcare Investments
Eli Lilly
Other known investors1 additional known investor
University of Oxford
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Evox Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Evox Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.